Chief Financial Officer · BlossomHill Therapeutics, Inc. · BlossomHill Therapeutics, Inc. — Employee Stock Option (Right to Buy)
Side
A
Value
—
Shares
56.7K
Price
—
Executed
Aug 6, 2026
Disclosed
Aug 10, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Aug 6 executedAug 10, 2026 disclosed
BLSM · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
BlossomHill Therapeutics, Inc. — Employee Stock Option (Right to Buy)
Ticker
BLSM
Shares
56.7K
Price per share
$0
Execution date (reported)
Aug 6, 2026
Owned after transaction
56.7K shares
Days from execution to publication
4
What this establishes
Keyes Jason A filed this Form 4 reporting a grant or award of BLSM on Aug 6, 2026. It became public on Aug 10, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Financial Officer
Keyes Jason Acik:0001678152
Issuer
BlossomHill Therapeutics, Inc.cik:0001839970
Revision history · 0
No field has changed since this record was first ingested.
